Companies Dominating the Biological Imaging Reagents Landscape
- Bayer AG
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Bracco
- Carl Zeiss
- Cell Signaling Technology
- Danaher
- General Electric Company
- Guerbet
- Jubilant Pharmova Limited
- Luminex Corporation
- Nikon Corporation
- Novartis AG
- Olympus Corporation
- Promega Corporation
- Sartorius AG
- Thermo Fisher Scientific Inc
Key players include major biotechnology firms and manufacturers focusing on reagents for fluorescence, microscopy, and other imaging modalities. The trend for specificity and sensitivity of products to cater to the differentiated needs in the biological imaging reagents market is propelling growth. For instance, in July 2024, the imaging segment of GE HealthCare reported revenues of USD 2.5 billion for the second quarter of last year and reflected flat revenue growth of USD 2.62 billion in organic imaging. The imaging EBIT grew by 3% to reach USD 286 million.
Major contributors are:
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2025, the industry size of biological imaging reagents is assessed at USD 14.27 billion.
The biological imaging reagents market size was over USD 13.37 billion in 2024 and is projected to reach USD 34.23 billion by 2037, witnessing around 7.5% CAGR during the forecast period i.e., between 2025-2037.
North America industry is set to hold largest revenue share of 33.7% by 2037, attributed to state-of-the-art research and healthcare facilities with imaging technologies.
The major players in the market include Luminex Corporation, Nikon Corporation, Novartis AG, Olympus Corporation, Promega Corporation, Sartorius AG, and others.
